Pharming Group N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
21 mrt 2011 - 10:18
Statutaire naam
Pharming Group N.V.
Titel
SANTARUS AND PHARMING ANNOUNCE RHUCIN POSTER AT AMERICAN ACADEMY OF ALLERGY, ASTHMA & IMMUNOLOGY 2011 ANNUAL MEETING
Bericht
SAN DIEGO and LEIDEN, The Netherlands (March 21, 2011) – Specialty biopharmaceutical company Santarus, Inc. (NASDAQ: SNTS) and biotech company Pharming Group NV (NYSE Euronext: PHARM) today announced new data on 62 patients with Hereditary Angioedema (HAE) who received repeat treatment with the investigational drug RHUCIN® (recombinant human C1 inhibitor) for 168 acute angioedema attacks. The median time to beginning of relief of symptoms across treatments for repeat attacks was approximately 60 minutes with response rates that were consistently 90% or greater. This open-label study was an extension of the randomized, double-blind, placebo-controlled study conducted by Pharming in North America. The findings were presented Sunday, March 20, 2011 in a poster session at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2011 Annual Meeting in San Francisco.
Gerelateerde downloads
Datum laatste update: 05 februari 2025